A topic in the Open Knowledge Graph — a free, open map of 15,290 topics and the order to learn them in.
Moral hazard in health insurance occurs when insurance coverage increases healthcare utilization because patients pay less than the full cost of care at the point of service. When the out-of-pocket price falls from the market price to a copayment or zero, patients consume care whose value to them is below its cost to produce — care that they would not have purchased at full price. The RAND Health Insurance Experiment (1974-1982), the most important experiment in health economics, demonstrated that cost-sharing significantly reduces utilization: patients assigned to free care used 25-30% more services than those with substantial cost-sharing. Critically, much of the additional utilization under free care was of low clinical value, though some was clinically important. The welfare implications are ambiguous: moral hazard generates deadweight loss (inefficient overconsumption), but cost-sharing may also deter valuable care, particularly among low-income and chronically ill populations.
Insurance exists to protect people from financial catastrophe — a $200,000 cancer treatment would bankrupt most families without coverage. But insurance creates a side effect: when someone else pays the bill, you use more of the product. This is moral hazard, and it is one of the central concepts in health economics because it creates a tension between the risk-protection function of insurance and the efficiency goal of consuming only care that is worth its cost.
The mechanism is straightforward. Without insurance, a patient facing a $500 specialist visit weighs the expected health benefit against $500. With insurance that requires only a $20 copay, the same patient weighs the benefit against $20. Many visits that are not worth $500 are worth $20, so utilization increases. The additional visits whose value falls between $20 and $500 represent the deadweight loss of moral hazard — care that costs more to produce than it is worth to the patient. The patient gains some benefit, but less than the cost, and the difference is a social loss.
The RAND Health Insurance Experiment provided definitive evidence. By randomly assigning families to different cost-sharing levels (eliminating selection bias), it showed that free care increased utilization by 25-30% compared to substantial cost-sharing. But the experiment also revealed that patients did not selectively reduce low-value care under cost-sharing — they reduced high-value preventive care and chronic disease management at roughly the same rate. Among the poorest, sickest participants, free care produced measurably better health outcomes. This finding complicates the simple deadweight-loss story: moral hazard generates waste, but cost-sharing designed to reduce moral hazard also deters beneficial care, with the greatest harm falling on vulnerable populations.
Modern insurance design attempts to navigate this tradeoff. Value-based insurance design (VBID) reduces cost-sharing for high-value services (preventive care, essential medications for chronic conditions) and increases it for low-value services (marginal imaging, brand-name drugs with generic equivalents). The idea is to align patient incentives with clinical value — removing the financial barrier to care that is worth its cost while maintaining deterrence of care that is not. This approach recognizes that moral hazard is not a uniform problem: the welfare consequences depend entirely on whether the additional utilization induced by insurance produces health value commensurate with its cost.